1st Edition
Handbook of Novel Psychoactive Substances What Clinicians Should Know about NPS
Handbook of Novel Psychoactive Substances (NPS) provides a comprehensive overview of the challenges that clinicians face when dealing with NPS and discusses how the profile of patients and their socio-demographic characteristics frame the serious public health concern that NPS pose. It presents various clinical cases, as well as detailed accounts of symptoms, psychopathology, toxicity, and overall clinical management that NPS require. This handbook brings together a unique collection of chapters written by leading experts in the field, who have felt the need to share their knowledge and experience to improve the clinical practice on NPS and the wellbeing of their patients.
Author biographies Foreword 1. Overcoming the NPS challenge: an introduction SECTION ONE NPS Users: Prevalence, Patterns, and Prevention 2. The need for clinical guidelines on NPS: NEPTUNE 3. NPS: epidemiology, user group characteristics, patterns, motives, and problems 4. The NPS crisis in British prisons 5. Current trends in performance- and image-enhancing substance use among gym goers, exercisers, and athletes SECTION TWO Clinical Recommendations and Best Practices Across Front-Line Health Professionals 6. NPS in emergency rooms: dealing with aggressiveness and psychomotor agitation 7. A sentinel and design model of evidence collection on acute drug and NPS toxicity: the Euro-Den Plus Project 8. Novel and traditional club substances' association to psychopathological and medical sequelae: the Ibiza project SECTION THREE Substances, Adverse Effects, and Clinical Management 9. Spice drugs, synthetic cannabinoids, and "Spiceophrenia" 10. Synthetic cannabinoids, opioids, and polydrug use: clinical implications 11. Synthetic cathinones and related fatalities in the United Kingdom 12. Marvin the Paranoid Android and Alice in Wonderland: two case reports of synthetic cathinones abuse 13. Clinical aspects related to methylphenidate-based NPS 14. The worldwide spread of "Herbal Highs": the case of Kratom 15. Clinical and medical management of conditions caused by MDMA or "Ecstasy" 16. Clinical effects of 2C-B abuse 17. "In and Out of the Hole": an exploration on phencyclidine derivatives 18. Fentanyl and related opioids: new trends, dangers, and management 19. Designer benzodiazepines: new challenges and treatment options 20. Misuse, recreational use, and addiction in relation to prescription medicines
Biography
Ornella Corazza, MA, PhD, is a Reader in Substance Addictions and Behaviours at the University of Hertfordshire (UK), where she leads a multidisciplinary team across a diverse portfolio in public health and drug policy research. Results of her work have been presented in over a hundred peer-reviewed publications, policy reports and invited lectures internationally.
Andres Roman-Urrestarazu, MD, PhD, specializes in the crossover of psychiatry, substance abuse, health economics, and international health policy. He is currently Gillings Fellow in Global Public Health at the University of Cambridge (UK) and assistant professor at Maastricht University (Netherlands). He has held appointments at Trinity Hall, Cambridge and the London School of Economics and Political Science, working extensively on substance misuse and New Psychoactive Substances.
